Skip to main content
Top
Published in: Clinical and Experimental Medicine 3/2011

01-09-2011 | Original Article

B7-H4 expression in various tumors determined using a novel developed monoclonal antibody

Authors: Yun Qian, Ling Shen, Linfang Cheng, Zhigang Wu, Hangping Yao

Published in: Clinical and Experimental Medicine | Issue 3/2011

Login to get access

Abstract

B7-H4, a new member of the B7 family, may participate in the negative regulation of cell-mediated immunity, while aberrant B7-H4 expression is detected in some tumors and it participates in the occurrence and development of the tumors. In this study, we developed one monoclonal antibody (mAb) whose clone No. was 4H8 against the extracellular domains of B7-H4 through immunization of Balb/c mice with the 3T3-mB7-H4 cells that expressed extrinsic B7-H4 stably. And we detected the expression characteristics of B7-H4 in various tumors using 4H8 mAb by enzyme-linked immunosorbent assay (ELISA), immunoprecipitation and immunohistochemistry (IHC) analysis. B7-H4 expression was significantly higher in the tumor tissues derived from uterus, breast, and colon than in their corresponding normal tissues. Further, the B7-H4 expression was related to the stage of the tumors. In contrast, B7-H4 expression did not differ significantly between the tumor tissues derived from the stomach and liver and the normal tissues. Different expression levels of B7-H4 in the tumors indicated that B7-H4 may be involved in tumor formation and development. Specific mAbs against B7-H4 will be useful in studying the role of B7-H4 in tumor pathogenesis and pathological process.
Literature
1.
go back to reference Sica GL, Choi IH, Zhu G, Tamada K, Wang SD, Tamura H, Chapoval AI, Flies DB, Bajorath J, Chen L (2003) B7–H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 18:849–861PubMedCrossRef Sica GL, Choi IH, Zhu G, Tamada K, Wang SD, Tamura H, Chapoval AI, Flies DB, Bajorath J, Chen L (2003) B7–H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 18:849–861PubMedCrossRef
2.
go back to reference Chen L (2004) Co-inhibitory molecules of the B7- CD28 family in the control of T cell immunity. Nat Rev Immunol 4:336–347PubMedCrossRef Chen L (2004) Co-inhibitory molecules of the B7- CD28 family in the control of T cell immunity. Nat Rev Immunol 4:336–347PubMedCrossRef
3.
go back to reference Schwartz RH (1990) A cell culture mode for T lymphocyte clonal anergy. Science 248:l349–1356CrossRef Schwartz RH (1990) A cell culture mode for T lymphocyte clonal anergy. Science 248:l349–1356CrossRef
4.
go back to reference Chambers CA (2001) The expanding world of co-stimulation: the two-signal model revisited. Trends Immunol 22:217–223PubMedCrossRef Chambers CA (2001) The expanding world of co-stimulation: the two-signal model revisited. Trends Immunol 22:217–223PubMedCrossRef
5.
go back to reference Choi IH, Zhu G, Sica GL, Strome SE, Cheville JC, Lau JS, Zhu Y, Flies DB, Tamada K, Chen L (2003) Genomic organization and expression analysis of B7–H4, an immune inhibitory molecule of the B7 family. J Immunol 171:4650–4654PubMed Choi IH, Zhu G, Sica GL, Strome SE, Cheville JC, Lau JS, Zhu Y, Flies DB, Tamada K, Chen L (2003) Genomic organization and expression analysis of B7–H4, an immune inhibitory molecule of the B7 family. J Immunol 171:4650–4654PubMed
6.
go back to reference Yigit R, Massuger LF, Figdor CG, Torensma R (2010) Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Oncol 117:366–372PubMedCrossRef Yigit R, Massuger LF, Figdor CG, Torensma R (2010) Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Oncol 117:366–372PubMedCrossRef
7.
go back to reference Sun Y, Wang Y, Zhao J, Gu M, Giscombe R, Lefvert AK, Wang X (2006) B7–H3 and B7–H4 expression in non-small-cell lung cancer. Lung Cancer 53:143–151PubMedCrossRef Sun Y, Wang Y, Zhao J, Gu M, Giscombe R, Lefvert AK, Wang X (2006) B7–H3 and B7–H4 expression in non-small-cell lung cancer. Lung Cancer 53:143–151PubMedCrossRef
8.
go back to reference Salceda S, Tang T, Kmet M, Munteanu A, Ghosh M, Macina R, Liu W, Pilkington G, Papkoff J (2005) The immunomodulatory protein B7–H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp Cell Res 306:128–141PubMedCrossRef Salceda S, Tang T, Kmet M, Munteanu A, Ghosh M, Macina R, Liu W, Pilkington G, Papkoff J (2005) The immunomodulatory protein B7–H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp Cell Res 306:128–141PubMedCrossRef
9.
go back to reference Cheng L, Jiang J, Gao R, Wei S, Nan F, Li S, Kong B (2009) B7–H4 expression promotes tumorigenesis in ovarian cancer. Int J Gynecol Cancer 19:1481–1486PubMedCrossRef Cheng L, Jiang J, Gao R, Wei S, Nan F, Li S, Kong B (2009) B7–H4 expression promotes tumorigenesis in ovarian cancer. Int J Gynecol Cancer 19:1481–1486PubMedCrossRef
10.
go back to reference Jiang J, Zhu Y, Wu C, Shen Y, Wei W, Chen L, Zheng X, Sun J, Lu B, Zhang X (2010) Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer. Cancer Immunol Immunother [Epub ahead of print] Jiang J, Zhu Y, Wu C, Shen Y, Wei W, Chen L, Zheng X, Sun J, Lu B, Zhang X (2010) Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer. Cancer Immunol Immunother [Epub ahead of print]
11.
go back to reference Qian Y, Yao HP, Cheng LF, Shen L, Gu LJ, Tao L, Zhang LH (2009) Expression and identification of recombinant mouse gene B7–H4. J Zhejiang Univ Med Sci 38:117–124 Qian Y, Yao HP, Cheng LF, Shen L, Gu LJ, Tao L, Zhang LH (2009) Expression and identification of recombinant mouse gene B7–H4. J Zhejiang Univ Med Sci 38:117–124
12.
go back to reference Yao HP, Luo YL, Feng L, Cheng LF, Lu Y, Li W, Wang MH (2006) Agonistic monoclonal antibodies potentiate tumorigenic and invasive activities of splicing variant of the RON receptor tyrosine kinase. Cancer Biol Ther 5:1179–1186PubMedCrossRef Yao HP, Luo YL, Feng L, Cheng LF, Lu Y, Li W, Wang MH (2006) Agonistic monoclonal antibodies potentiate tumorigenic and invasive activities of splicing variant of the RON receptor tyrosine kinase. Cancer Biol Ther 5:1179–1186PubMedCrossRef
13.
go back to reference Nelson PN, Reynolds GM, Waldron EE, Ward E, Giannopoulos K, Murray PG (2000) Monoclonal antibodies. Mol Pathol 53:111–117PubMedCrossRef Nelson PN, Reynolds GM, Waldron EE, Ward E, Giannopoulos K, Murray PG (2000) Monoclonal antibodies. Mol Pathol 53:111–117PubMedCrossRef
14.
go back to reference Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155–168PubMed Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155–168PubMed
15.
go back to reference Zang XX, Loke P, Kim J, Murphy K, Waitz R, Allison JP (2003) B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci USA 100:10388–10392PubMedCrossRef Zang XX, Loke P, Kim J, Murphy K, Waitz R, Allison JP (2003) B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci USA 100:10388–10392PubMedCrossRef
16.
go back to reference Prasad DVR, Richards S, Mai XM, Dong C (2003) B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity 18:863–873PubMedCrossRef Prasad DVR, Richards S, Mai XM, Dong C (2003) B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity 18:863–873PubMedCrossRef
17.
go back to reference Cheng L, Jiang J, Gao R, Wei S, Nan F, Li S, Kong B (2009) B7–H4 expression promotes tumorigenesis in ovarian cancer. Int J Gynecol Cancer 19:1481–1486PubMedCrossRef Cheng L, Jiang J, Gao R, Wei S, Nan F, Li S, Kong B (2009) B7–H4 expression promotes tumorigenesis in ovarian cancer. Int J Gynecol Cancer 19:1481–1486PubMedCrossRef
18.
go back to reference Tringler B, Zhuo S, Pilkington G, Torkko KC, Singh M, Lucia MS, Heinz DE, Papkoff J, Shroyer KR (2005) B7–h4 is highly expressed in ductal and lobular breast cancer. Clin Cancer Res 11:1842–1848PubMedCrossRef Tringler B, Zhuo S, Pilkington G, Torkko KC, Singh M, Lucia MS, Heinz DE, Papkoff J, Shroyer KR (2005) B7–h4 is highly expressed in ductal and lobular breast cancer. Clin Cancer Res 11:1842–1848PubMedCrossRef
19.
go back to reference Tringler B, Liu W, Corral L, Torkko KC, Enomoto T, Davidson S, Lucia MS, Heinz DE, Papkoff J, Shroyer KR (2006) B7–H4 overexpression in ovarian tumors. Gynecol Oncol 100:44–52PubMedCrossRef Tringler B, Liu W, Corral L, Torkko KC, Enomoto T, Davidson S, Lucia MS, Heinz DE, Papkoff J, Shroyer KR (2006) B7–H4 overexpression in ovarian tumors. Gynecol Oncol 100:44–52PubMedCrossRef
20.
go back to reference Miyatake T, Tringler B, Liu W, Liu SH, Papkoff J, Enomoto T, Torkko KC, Dehn DL, Swisher A, Shroyer KR (2007) B7–H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration. Gynecol Oncol 106:119–127PubMedCrossRef Miyatake T, Tringler B, Liu W, Liu SH, Papkoff J, Enomoto T, Torkko KC, Dehn DL, Swisher A, Shroyer KR (2007) B7–H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration. Gynecol Oncol 106:119–127PubMedCrossRef
21.
go back to reference Krambeck AE, Thompson RH, Dong H, Lohse CM, Park ES, Kuntz SM, Leibovich BC, Blute ML, Cheville JC, Kwon ED (2006) B7–H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Nati Acad Sci USA 103:10391–10396CrossRef Krambeck AE, Thompson RH, Dong H, Lohse CM, Park ES, Kuntz SM, Leibovich BC, Blute ML, Cheville JC, Kwon ED (2006) B7–H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Nati Acad Sci USA 103:10391–10396CrossRef
22.
go back to reference Awadallah NS, Shroyer KR, Langer DA, Torkko KC, Chen YK, Bentz JS, Papkoff J, Liu W, Nash SR, Shah RJ (2008) Detection of B7–H4 and p53 in pancreatic cancer: potential role as a cytological diagnostic adjunct. Pancreas 36:200–206PubMedCrossRef Awadallah NS, Shroyer KR, Langer DA, Torkko KC, Chen YK, Bentz JS, Papkoff J, Liu W, Nash SR, Shah RJ (2008) Detection of B7–H4 and p53 in pancreatic cancer: potential role as a cytological diagnostic adjunct. Pancreas 36:200–206PubMedCrossRef
23.
go back to reference Simon I, Zhuo S, Corral L, Diamandis EP, Sarno MJ, Wolfert RL, Kim NW (2006) B7–H4 Is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res 66:1570–1575PubMedCrossRef Simon I, Zhuo S, Corral L, Diamandis EP, Sarno MJ, Wolfert RL, Kim NW (2006) B7–H4 Is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res 66:1570–1575PubMedCrossRef
24.
go back to reference Dube DH, Bertozzi CR (2005) Glycans in cancer and inflammation-potential for therapeutics and diagnostics. Nat Rev Drug Discov 4:477–488PubMedCrossRef Dube DH, Bertozzi CR (2005) Glycans in cancer and inflammation-potential for therapeutics and diagnostics. Nat Rev Drug Discov 4:477–488PubMedCrossRef
25.
go back to reference Park GB, Song H, Kim YS, Sung M, Ryu JW, Lee HK, Cho DH, Kim D, Lee WJ, Hur DY (2009) Cell cycle arrest induced by engagement of B7–H4 on Epstein-Barr virus-positive B-cell lymphoma cell lines. Immunology 128:360–368PubMedCrossRef Park GB, Song H, Kim YS, Sung M, Ryu JW, Lee HK, Cho DH, Kim D, Lee WJ, Hur DY (2009) Cell cycle arrest induced by engagement of B7–H4 on Epstein-Barr virus-positive B-cell lymphoma cell lines. Immunology 128:360–368PubMedCrossRef
Metadata
Title
B7-H4 expression in various tumors determined using a novel developed monoclonal antibody
Authors
Yun Qian
Ling Shen
Linfang Cheng
Zhigang Wu
Hangping Yao
Publication date
01-09-2011
Publisher
Springer Milan
Published in
Clinical and Experimental Medicine / Issue 3/2011
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-010-0125-2

Other articles of this Issue 3/2011

Clinical and Experimental Medicine 3/2011 Go to the issue